Medexprim, a leading innovator in the field of Real-World Data and healthcare solutions, is pleased to announce its participation in the upcoming European Society for Medical Oncology (ESMO) Congress 2023, to be held from October 20 to 24 in Madrid.

Medexprim, renowned for its extensive network of leading university hospitals, cancer centers, and data partners, is at the forefront of leveraging Real-World Data to transform the landscape of cancer research. The company’s presence at ESMO Congress, Booth #558, offers a unique opportunity for researchers, and Pharmaceutical, MedTech, and BioTech representatives to gain insights into such critical areas as External Control Arms, Qualification of Sites for Clinical Research, Patient Identification, or Biomarker Development.

“At ESMO Congress 2023, we invite the global oncology community to join us at Booth #558 in exploring the cutting-edge possibilities of Real-World Data in accelerating precision oncology clinical research” said Romain Cazavan, CEO of Medexprim.

For further details and to schedule a meeting with Medexprim at the event, please visit Meet Us | Medexprim.

French version of the press release

About Medexprim
European leader in imaging & clinical data extraction, Medexprim bridges leading hospitals and pharmaceutical companies. Real-World data specialist, we help hospitals drive their research strategy and valorize their data. We provide our partners with secure access to multimodal, multicentric datasets for clinical research projects in oncology, cardiology, neurology, and rare diseases. We aim to structure the Real-World clinical and imaging data ecosystem in Europe to accelerate precision medicine.

Linkedin
Press contact: Anne-Sophie Labeta
aslabeta@medexprim.com